Search results
Results from the WOW.Com Content Network
A main target of PEA is proposed to be the peroxisome proliferator-activated receptor alpha (PPAR-α). [3] [4] PEA also has affinity to cannabinoid-like G-coupled receptors GPR55 and GPR119. [5] PEA cannot strictly be considered a classic endocannabinoid because it lacks affinity for the cannabinoid receptors CB1 and CB2. [6]
Targeted alpha-particle therapy (or TAT) is an in-development method of targeted radionuclide therapy of various cancers. It employs radioactive substances which undergo alpha decay to treat diseased tissue at close proximity. [1] It has the potential to provide highly targeted treatment, especially to microscopic tumour cells.
An alpha privative or, rarely, [1] privative a (from Latin alpha prīvātīvum, from Ancient Greek α στερητικόν) is the prefix a-or an-(before vowels) that is used in Indo-European languages such as Sanskrit and Greek and in words borrowed therefrom to express negation or absence, for example the English words of Greek origin atypical, anesthetic, and analgesic.
Another form of targeted therapy involves the use of nanoengineered enzymes to bind to a tumor cell such that the body's natural cell degradation process can digest the cell, effectively eliminating it from the body. Targeted cancer therapies are expected to be more effective than older forms of treatments and less harmful to normal cells.
Eftilagimod alpha (INN; [1] development code IMP321 or efti) is a large-molecule cancer drug being developed by the clinical-stage biotechnology company Immutep. Efti is a soluble version of the immune checkpoint molecule LAG-3 .
Cancer Cell is a peer-reviewed scientific journal scientific journal that publishes articles that provide major advances in cancer research and oncology. The journal considers manuscripts that answer important questions relevant to naturally occurring cancers.
The 7(S) enantiomer bound with micromolar affity to PPAR alpha with 10 fold higher affinity compared to the (R) enantiomer and could trigger dendritic activation. [1] PPARα (alpha) is the main target of fibrate drugs, a class of amphipathic carboxylic acids (clofibrate, gemfibrozil, ciprofibrate, bezafibrate, and fenofibrate).
Cancer Letters is a peer-reviewed medical journal established in 1975 that focuses on the rapid publication of original research on multidisciplinary aspects of cancer. The editor-in-chief is M. Schwab .